Tissue factor pathway inhibitor can interact with platelets

Journal of Immunological Methods

Volumn 266, Issue 1-2, 2002, Pages 181-184

  Nishioka, Takuya ^a   Yokota, Masaharu ^a   Hino, Masayuki ^a   Tsuda, Izumi ^a   Tatsumi, Noriyuki ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

GPIIb IIIa; Platelet aggregation; Tissue factor pathway inhibitor

Indexed keywords

ANTIBODY; BUFFER; CALCIUM CHLORIDE; FIBRINOGEN RECEPTOR; TISSUE FACTOR PATHWAY INHIBITOR;

ADULT; ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; NORMAL HUMAN; PRIORITY JOURNAL; THROMBOCYTE; THROMBOCYTE AGGREGATION;

ANTIBODIES, MONOCLONAL; BLOOD PLATELETS; HUMANS; KINETICS; LIPOPROTEINS; PLATELET AGGREGATION; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX;

EID: 0036679894     PISSN: 00221759     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-1759(02)00145-X     Document Type: Article

References (12)

1. Cultured normal human hepatocytes do not synthesize lipoprotein-associated coagulation inhibitor: Evidence that endothelium is the principal site of its synthesis
2. Tissue-factor pathway inhibitor and lipoproteins: Evidence for association with and regulation by LDL in human plasma
3. Prevention of arterial reocclusion after thrombolysis with recombinant lipoprotein-associated coagulation inhibitor
4. Measurement of tissue factor pathway inhibitor in normal and post-heparin plasma
5. The role of von Willebrand factor and fibrinogen in platelet aggregation under varying shear stress
6. The present status of tissue factor pathway inhibitor
7. Purification and characterization of the lipoprotein associated coagulation inhibitor from human plasma
8. Plasma antigen levels of the lipoprotein associated coagulation inhibitor in patient samples
9. Tissue factor pathway inhibitor (TFPI) - An update
10. Tissue factor pathway inhibitor as a universal anticoagulant for use in clinical laboratory tests
11. Distribution of tissue factor pathway inhibitor in normal and malignant human tissues
12. Cloning and characterization of a cDNA coding for the lipoprotein-associated coagulation inhibitor shows that it consists of three tandem Kunitz-type inhibitory domains